3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Ovarian Neoplasms
3
Recurrence
2
Neoplasms
2
Hypersensitivity
2
Uterine Neoplasms
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoadjuvant Therapy
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Adenocarcinoma
1
Interventions
Docetaxel
137
Prednisone
120
Abiraterone Acetate
91
Leuprolide
86
enzalutamide
84
Radiotherapy
59
bicalutamide
56
Magnetic Resonance Spectroscopy
54
Goserelin
54
Androgen Antagonists
51
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
47
apalutamide
44
abiraterone
34
Radiosurgery
31
Specimen Handling
30
gallium 68 PSMA-11
29
Gonadotropin-Releasing Hormone
29
cabazitaxel
28
Carboplatin
27
darolutamide
26
Estramustine
24
luprolide acetate gel depot
23
relugolix
22
Metformin
22
Triptorelin Pamoate
20
sipuleucel-T
19
radium Ra 223 dichloride
19
Radiation
19
pembrolizumab
18
deltacortene
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Prostatic Neoplasms
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Clear all
NCT07268794
2025-12-08
CONVERT-HB1
Fudan University
Phase 2
Not yet recruiting
112 enrolled